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Introduction
Gout is a systemic inflammatory arthritis characterized by the 
deposition of monosodium urate (MSU) crystals due to hyperuri-
cemia. This is defined as serum uric acid levels above 6.8mg/dL 
and is due to impaired excretion and/or overproduction of 
uric acid1. Atrial fibrillation (AF) is a multifactorial condition 
whose prevalence increases with age2–4. Previous studies have 
suggested a correlation between pro-inflammatory conditions such 
as gout and cardiovascular diseases5–7, and have explored the link 
between gout and AF8–13. Given the increasing prevalence and 
incidence of gout14, there is a need to quantify the relationship 
between gout and the risk of AF.
Methods
The meta-analysis was conducted in accordance with the MOOSE 
checklist. PubMed and Embase were searched for studies report-
ing the association between gout and AF using the search 
terms: (‘Gout’ and ‘Arrhythmia’). The search period was from 
the start of the database to 3rd August 2018 with no language 
restrictions. Two researchers (KSKL and MG) independently 
conducted the search. Any disagreement was resolved by 
adjudication from a third reviewer (GT). Study selection was 
carried out by screening titles of full publications to determine 
compliance with the following inclusion criteria: (1) retrospec-
tive or prospective cohort studies in human subjects with gout 
and non-gout control group; (2) AF occurrence was reported; 
(3) adjusted hazard ratio (aHR) with 95% confidence intervals 
(95% CI) was reported or could be calculated. As all of the 
included studies reported sufficient information, contact with the 
original study authors was not required.
The quality assessment of these studies included in our meta- 
analysis was performed using the Newcastle-Ottawa Quality 
Assessment Scale (NOS). The point score system evaluated the 
categories of study participant selection, comparability of the 
results and quality of the outcomes. The following characteristics 
were assessed: (1) representativeness of the exposed cohort; 
(2) selection of the non-exposed cohort; (3) ascertainment of 
exposure; (4) demonstration that outcome of interest was not 
present at the start of the study; (5) comparability of cohorts on the 
basis of the design or analysis; (6) assessment of outcomes; 
(7) follow-up period sufficiently long for outcomes to occur; and 
(8) adequacy of follow-up of cohorts.
Data were entered in prespecified spreadsheet in Microsoft Excel. 
The extracted data elements consisted of (1) surname of first 
author and publication year; (2) sample size of gout and non-gout 
cohorts; (3) follow-up duration; (4) population characteristics (age, 
gender, diabetes mellitus, hypertension, ischemic heart disease 
or coronary artery disease, chronic heart failure, hyperlipidemia, 
chronic obstructive pulmonary disease, liver disease).
Statistical analysis was performed using Review Manager 
(Version 5.3). Heterogeneity was assessed by the I2 statistic. I2>50% 
reflects significant statistical heterogeneity. Therefore, a random-
effects model with the inverse variance heterogeneity method 
was used. Subgroup analyses were not performed due to the fact 
that not all studies consistently reported the outcomes for the same 
subgroups.
Results
A total of 97 entries were retrieved from 75 and 22 from PubMed 
and Embase, respectively. Of these, four observational studies 
(three cohort studies, one case-control study) including 659,094 
patients were included (Figure 1)4–7. The main characteris-
tics of the studies are summarised in Table 1. The four different 
cohorts were recruited from the United Kingdom, United 
States and Taiwan. All included studies had NOS scores >= 7, 
indicating that they were of high quality (Table 2 and Table 3). 
Our meta-analysis demonstrated that gout was significantly 
associated with increased risk of AF (adjusted HR = 1.31; 
95%CI: 1.00- 1.70; P = 0.05; I2 = 99%) (Figure 2). This was 
observed after adjusting for comorbidities and confounders 
of AF. 
Figure 1. Flow chart for the study screening and selection process.
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Table 3. NOS risk of bias scale for included cohort studies.
Selection Outcome
Studies Representativeness 
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Figure 2. Hazard ratio for the risk of atrial fibrillation in the gout population relative to the non-gout population.
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Discussion
Atrial cardiomyopathy, in particularly AF, is a significant 
clinical problem because it predisposes to stroke, which can be 
debilitating and increase mortality15–17. Numerous predictors 
of AF have been identified, including co-morbid conditions18, 
blood biomarkers19–26, and electrocardiographic predictors27–29. 
The main finding of this meta-analysis is that gout is associated 
with a 31% higher risk of AF after adjusting for significant 
comorbidities and confounders.
Several mechanisms have been proposed to explain this relation-
ship with reactive oxygen species as a critical player in the pro-
inflammatory process13,30. High serum uric acid levels in gout 
patients overwhelm the uric acid transporter (URAT1) and their 
influx causes intracellular accumulation of urate, which in turn 
stimulates NADPH oxidase and subsequent reactive oxygen spe-
cies (ROS) production. ROS produced activates the downstream 
ERK1/2 pathway and upregulates Kv1.5 protein expression, 
resulting in the attenuation of atrial cellular action potential and 
electrical remodelling of the left atrium, as illustrated in mice 
models31. Furthermore, the renin-angiotensin-aldosterone system 
that becomes activated by high urate acid levels in gout 
patients. Subsequent studies into gout treatment can prevent 
AF and lower its recurrence rate after pulmonary vein isola-
tion (PVI) ablation32,33. In preclinical studies, urate-lowering 
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Total (95% CI)
Heterogeneity: Tau2 = 0.07; Chi2 = 277.65, df = 3 (P < 0.00001); I2 = 99%
Test for overall effect: Z = 1.98 (P = 0.05)
Hazard Ratio
IV, Random, 95% CI
Hazard Ratio
IV, Random, 95% CI
1.31 [1.00, 1.70]
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elling of the cardiac chambers33,34. The NLRP3-inflamma-
some also contributes to the pathogenesis underlying AF in gout 
and can be activated by MSU crystals in gout35. Its activation 
triggers the maturation and production of the pro-inflammatory 
cytokine interleukin-1β (IL-1β), which upregulates the expres-
sion of TGF-β1, a key mediator for atrial fibrosis36, which can 
lead to atrial conduction abnormalities37,38, promoting AF by 
re-entry39,40.
The main strength is that it included the largest cohort of ~660000 
patients. However, the following limitations remain. Firstly, as 
the included studies were retrospective, they are susceptible 
to bias as in all studies of this study design. Secondly, only 
four studies were included and future studies are needed to 
confirm the relationship between gout and AF. Thirdly, defini-
tions of AF also differed between studies. It was based on phy-
sician diagnosis or ICD-9 criteria from data obtained using 
administrative databases. Finally, the type of AF, such as 
paroxysmal, sustained or permanent, was not reported. These 
limitations could explain the high heterogeneity observed in this 
meta-analysis.
In conclusion, our meta-analysis confirms the significant 
relationship between gout and AF. More data are needed to 
determine whether this risk can be adequately reduced by 
urate-lowering therapy.
Data availability
All data underlying the results are available as part of the article 
and no additional source data are required.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
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